Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
Authors: Richard B. Warren, Curdin Conrad, Peter Foley, Lars Iversen, Richard G. Langley, Georgios Kokolakis, Leah Davis, Veerle Vanvoorden, Susanne Wiegratz, Joseph F. Merola